1
|
Sobolewska V, Duff H, Craighead F, Macpherson I, Veiraiah A, Dummer S, Lockman KA. Improving care for patients in the outlying wards: Lessons from patients' care experience. Acute Med 2022; 21:80-85. [PMID: 35681181 DOI: 10.52964/amja.0902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
IMPORTANCE Overcrowding in hospitals and lack of capacity in general medical wards can result in a medical patient being transferred to other specialty wards often referred as 'outlying' or 'boarding' wards. OBJECTIVES We explored the experiences of our outlying patients to identify local factors that affect their care experience and inform interventions that could improve their care deliveries and outcomes. DESIGN, SETTING, AND PARTICIPANTS Qualitative interviews using semi-structured questions were conducted in 21 medical patients from a mixture of specialty wards in a large tertiary NHS hospital. MAIN OUTCOMES AND MEASURES Perceptions of the factors contributing to the experience of being a patient on a boarding ward, and potential solutions. RESULTS Almost all participants reported experiences of good care in an outlying ward. Positive comments highlighted good nursing care, restful environment and a strong focus on patient-centred care. However, none of the participants could identify the team or consultant responsible for their care and this was linked to multiple doctors being involved in the patient's care. Participants also perceived that the frequency of review was reduced and occurred much later in the day than that experienced in the medical ward. Most felt indifferent about the care ownership, timing and frequency of review but in some cases, this led to confusion and the perception of poor progress. Further, participants felt that they had to actively seek information relating to clinical progress. Negative experience of discharge planning was also reported. The associated themes included conflicting information and delays in social care provision. This led to anxiety, frustration and the perception of being a barrier to patient flow. CONCLUSIONS AND RELEVANCE Patient experience of the outlying ward is positive, and this can provide a foundation for improvement. Our findings suggest that better care processes and improved communication are needed to promote equity and quality of care. However, this should be complemented with efforts to overcome wider challenges that affect the entire continuum of flow within the healthcare system.
Collapse
Affiliation(s)
- V Sobolewska
- MBChB, NHS Lothian, Department of Acute and General Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, Scotland, United Kingdom
| | - H Duff
- MBChB, NHS Lothian, Department of Acute and General Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, Scotland, United Kingdom
| | - F Craighead
- MBChB, NHS Lothian, Department of Acute and General Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, Scotland, United Kingdom
| | - I Macpherson
- MBChB, Gut Group, University of Dundee, Dundee, UK. ORCID ID https://orcid.org/0000-0003-0443-2073, Department of Acute and General Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, Scotland, United Kingdom
| | - A Veiraiah
- MBBS, NHS Lothian, Department of Acute and General Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, Scotland, United Kingdom
| | - S Dummer
- MBChB, NHS Lothian, Department of Acute and General Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, Scotland, United Kingdom
| | - K A Lockman
- MB Bch MD FRCP, NHS Lothian, Department of Acute and General Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, Scotland, United Kingdom
| |
Collapse
|
2
|
Cheung C, Laksman Z, Roberts J, Green M, Healey J, Sanatani S, Arbour L, Leather R, Chauhan V, Steinberg C, Angaran P, Duff H, Chakrabarti S, Simpson C, Talajic M, Tadros R, Seifer C, Gardner M, Krahn A. ARRHYTHMIC OUTCOMES IN CARDIAC ARREST SURVIVORS WITH PRESERVED EJECTION FRACTION REGISTRY (CASPER). Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
3
|
Brodehl A, Williams T, Rezazadeh S, Munsie N, Duff H, Childs S, Gerull B. P1601Mutations in ILK (integrin linked kinase) are associated with human arrhythmogenic cardiomyopathy and decreased survival in zebrafish. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- A. Brodehl
- Libin Cardiovascular Institute of Alberta - University of Calgary, Calgary, Canada
| | - T. Williams
- Comprehensive Heart Failure Center (CHFC), Internal Medicine, Wurzburg, Germany
| | - S. Rezazadeh
- Libin Cardiovascular Institute of Alberta - University of Calgary, Calgary, Canada
| | - N. Munsie
- University of Calgary, Department of Biochemistry and Molecular Biology, Calgary, Canada
| | - H. Duff
- Libin Cardiovascular Institute of Alberta - University of Calgary, Calgary, Canada
| | - S.J. Childs
- University of Calgary, Department of Biochemistry and Molecular Biology, Calgary, Canada
| | - B. Gerull
- Comprehensive Heart Failure Center (CHFC), Internal Medicine, Wurzburg, Germany
| | | |
Collapse
|
4
|
Alshehri M, Semeniuk L, Exner D, Mardell A, Zygun D, Sheldon R, Wagel S, Schnell G, Duff H. ABSENCE OF A J-WAVE MAY BE PREDICTIVE OF WORSE OUTCOMES DURING THERAPEUTIC HYPOTHERMIA IN POST CARDIAC ARREST PATIENTS. Can J Cardiol 2016. [DOI: 10.1016/j.cjca.2016.07.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Abstract
Introduction: Current National Institute for Health and Care Excellence (NICE) guidelines recommend the use of Low Molecular Weight Heparin (LMWH) for one month post-operatively in abdominal and pelvic cancer surgery to reduce risk of venous thromboembolism. We audited the prescription of LMWH at discharge and the compliance of patients with LMWH post-operatively and instigated measures to improve compliance. Materials and Methods: All patients undergoing major urological surgery from November 2011 to April 2012 were audited, with data collected on evidence of post-operative prescription (from discharge summaries). Patients within this 3-month period were questioned regarding compliance following discharge. Following this, changes were instigated to improve compliance (earlier discussion of post-operative LMWH administration in clinic, improved patient and junior doctor education). All patients undergoing surgery from November 2012 to June 2013 were identified and a re-audit completed. Results: Post-operative prescription of LMWH improved overall from 73% to 88%. Patient compliance to complete LMWH course improved from 23% to 88%. At re-audit, 97% of patients felt that training was adequate, and 94% of patients understood the rationale for taking LMWH at re-audit. Conclusion: Education of junior doctors improved prescription of LMWH at discharge. Improved patient education improves community LMWH use compliance post-discharge.
Collapse
Affiliation(s)
| | - E Upchurch
- Great Western Hospital, Swindon, England
| | - H Duff
- Derriford Hospital, England
| | | |
Collapse
|
6
|
Teng G, Duff H, Belke D, Turnbull J, Meijndert C, Chen Y, O'Brien E, Fedak P. TETRANDRINE REVERSES HUMAN CARDIAC MYOFIBROBLAST ACTIVATION AND MYOCARDIAL FIBROSIS. Can J Cardiol 2014. [DOI: 10.1016/j.cjca.2014.07.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
7
|
Gerull B, Kuriachan V, Clegg R, Exner D, Ferrier R, Desmarais S, Gordon P, Duff H. Next-generation sequencing identifies multiple disease associated variants in inherited heart conditions. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht308.p2299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Roach D, Morck M, Sheldon R, Duff H. 632 Auto-Entrainment Risk Assessment in Heart Failure. Can J Cardiol 2012. [DOI: 10.1016/j.cjca.2012.07.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
9
|
Hallstrom AP, McAnulty JH, Wilkoff BL, Follmann D, Raitt MH, Carlson MD, Gillis AM, Shih HT, Powell JL, Duff H, Halperin BD. Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators. J Am Coll Cardiol 2001; 37:1093-9. [PMID: 11263614 DOI: 10.1016/s0735-1097(00)01208-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES The goal of this study was to identify subgroups of arrhythmia patients who do not benefit from use of the implantable cardiac defibrillator (ICD). BACKGROUND Treatment of serious ventricular arrhythmias has evolved toward more common use of the ICD. Since estimates of the cost per year of life saved by ICD therapy vary from $25,000 to perhaps $125,000, it is important to identify patient subgroups that do not benefit from the ICD. METHODS Data for 491 ICD patients enrolled in the Antiarrhythmics Versus Implantable Defibrillators Study were used to create a hazards model relating baseline factors to time to first recurrent arrhythmia. The model was used to predict the hazard for recurrent arrhythmia among all trial patients. A priori cut points provided lower and higher recurrent arrhythmia risk strata. For each stratum the incremental years of life due to ICD versus antiarrhythmic drug therapy were calculated. RESULTS Factors that predicted recurrent arrhythmia were: ventricular tachycardia as the index arrhythmia, history of cerebrovascular disease, lower left ventricular ejection fraction, a history of any tachyarrhythmia before the index event and the absence of revascularization after the index event. Survival times (over a follow-up of three years) were identical in each arm of the lowest risk sextile (survival advantage 0.03 +/- 0.12 [se] years), while the survival advantage for patients above the first sextile was 0.27 +/- 0.07 (se) years (two-sided p = 0.05). CONCLUSIONS Patients presenting with an isolated episode of ventricular fibrillation in the absence of cerebrovascular disease or history of prior arrhythmia who have undergone revascularization or who have moderately preserved left ventricular function (left ventricular ejection fraction > 0.27) are not likely to benefit from ICD therapy compared with amiodarone therapy.
Collapse
|
10
|
Abstract
Developmental changes in electrocardiogram (ECG) and response to selective K(+) channel blockers were assessed in conscious, unsedated neonatal (days 1, 7, 14) and adult male mice (>60 days of age). Mean sinus R-R interval decreased from 120 +/- 3 ms in day 1 to 110 +/- 3 ms in day 7, 97 +/- 3 ms in day 14, and 81 +/- 1 ms in adult mice (P < 0.001 by ANOVA; all 3 groups different from day 1). In parallel, the mean P-R interval progressively decreased during development. Similarly, the mean Q-T interval decreased from 62 +/- 2 ms in day 1 to 50 +/- 2 ms in day 7, 47 +/- 8 ms in day 14 neonatal mice, and 46 +/- 2 ms in adult mice (P < 0.001 by ANOVA; all 3 groups are significantly different from day 1). Q-T(c) was calculated as Q- interval. Q-T(c) significantly shortened from 179 +/- 4 ms in day 1 to 149 +/- 5 ms in day 7 mice (P < 0.001). In addition, the J junction-S-T segment elevation observed in day 1 neonatal mice resolved by day 14. Dofetilide (0.5 mg/kg), the selective blocker of the rapid component of the delayed rectifier (I(Kr)) abolished S-T segment elevation and prolonged Q-T and Q-T(c) intervals in day 1 neonates but not in adult mice. In contrast, 4-aminopyridine (4-AP, 2.5 mg/kg) had no effect on day 1 neonates but in adults prolonged Q-T and Q-T(c) intervals and specifically decreased the amplitude of a transiently repolarizing wave, which appears as an r' wave at the end of the apparent QRS in adult mice. In conclusion, ECG intervals and configuration change during normal postnatal development in the mouse. K(+) channel blockers affect the mouse ECG differently depending on age. These data are consistent with the previous findings that the dofetilide-sensitive I(Kr) is dominant in day 1 mice, whereas 4-AP-sensitive currents, the transiently repolarizing K(+) current, and the rapidly activating, slowly inactivating K(+) current are the dominant K(+) currents in adult mice. This study provides background information useful for assessing abnormal development in transgenic mice.
Collapse
Affiliation(s)
- L Wang
- Department of Medicine, University of Calgary, Calgary, Alberta, Canada T2N 4N1
| | | | | |
Collapse
|
11
|
Abstract
BACKGROUND Quinine is the diastereomer of quinidine. In dogs, it has similar effects on conduction time but does not prolong epicardial repolarization time or ventricular refractoriness. It has antiarrhythmic effects in both cats and dogs. We assessed the antiarrhythmic potential of quinine in suppressing ventricular arrhythmias in humans. METHODS AND RESULTS Patients underwent open-label, dose-ranging trials of quinine with daily doses of 600, 1200, and 1800 mg in a twice-daily dosing regimen. In 17 patients with frequent spontaneous ventricular ectopy, oral quinine suppressed arrhythmia in 11 of 12 patients who finished the study and was not tolerated by 4 patients, and 1 patient withdrew from the study. The mean effective daily dosage was 927 mg, the mean effective trough serum level was 11 mumol/L (range, 4 to 17 mumol/L), and the half-life was 20 +/- 7 hours. In a second open-label, dose-ranging trial in 10 patients with inducible ventricular tachycardia and reduced left ventricular systolic function (left ventricular ejection fraction, 35 +/- 16%), quinine suppressed inducibility of ventricular tachycardia in 3 of 10 patients. At a basic pacing cycle length of 500 milliseconds, ventricular effective refractory period was prolonged (279 +/- 21 versus 247 +/- 10 milliseconds, quinine versus drug free, P = .003). In the remaining patients, ventricular tachycardia cycle length was prolonged (373 +/- 48 versus 253 +/- 30 milliseconds, quinine versus drug free, P < .001). The corrected QT interval was not prolonged. CONCLUSIONS Quinine is an effective and convenient antiarrhythmic drug for the suppression of ventricular arrhythmias in humans.
Collapse
Affiliation(s)
- R Sheldon
- Cardiovascular Research Group, University of Calgary, Alberta, Canada
| | | | | |
Collapse
|
12
|
|
13
|
Sheldon R, Thakore E, Wilson L, Duff H. Interaction of drug metabolites with the class I antiarrhythmic drug receptor on rat cardiac myocytes. J Pharmacol Exp Ther 1994; 269:477-81. [PMID: 8182514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
The use of class I antiarrhythmic drugs may be complicated by the presence of active metabolites. A simple technique to predict the clinical activity of these metabolites might help with the clinical use of these drugs. We tested the hypothesis that drug metabolites bind to the class I drug receptor, but that only clinically active metabolites bind appreciably at clinically observed concentrations. Using a radioligand assay, we determined whether 13 class I drug metabolites interacted with a receptor for class I drugs associated with the cardiac sodium channel. The radioligand was [3H]batrachotoxinin A20 benzoate. All 13 metabolites bound to the drug receptor with IC50 values of 2.7 to 375 microns, and a mean Hill number of 1.0 +/- 0.3. All of the seven active metabolites (N-acetylprocainamide, mono-N-dealkyldisopyramide, 5-hydroxypropafenone, N-desisopropylpropafenone, 0-demethylencainide, 3-methoxy-0-demethylencainide and desethylamiodarone) each bound to the receptor at concentrations approaching their clinical concentrations, whereas none of the six inactive metabolites (quinidine-N-oxide, 3-hydroxyquinidine, glycinexylidide, monoethylglycinexylidide, N-demethylencainide and N,0-demethylencainide) did. Using a relationship which correlates drug IC50 values and clinically observed drug concentrations we calculated predicted clinical concentrations if the metabolites were clinically active. A predicted/observed ratio < or = 10 correlates with 100% positive and negative accuracies whether a drug metabolite has clinical activity. Thus a simple radioligand assay predicts whether class I drugs have clinical activity.
Collapse
Affiliation(s)
- R Sheldon
- Cardiovascular Research Group, University of Calgary, Alberta, Canada
| | | | | | | |
Collapse
|
14
|
Abstract
The pharmacokinetics of a single intravenous dose of propafenone were studied in subjects with normal renal function (n = 5), renal insufficiency (n = 5), and renal failure (n = 3). No difference in central volume of distribution, total ischemic clearance or terminal half-life existed. None of the pharmacokinetic parameters examined correlated to creatinine clearance. Within the confines of the small number of patients studied, there does not appear to be any effect of renal insufficiency or failure on single-dose propafenone disposition.
Collapse
Affiliation(s)
- E Burgess
- Department of Medicine, University of Calgary, Alberta, Canada
| | | | | |
Collapse
|
15
|
Abstract
A RIA for alpha-human atrial natriuretic peptide (alpha hANP) in plasma was developed and used to study the immunoreactive components secreted by the heart and circulating in peripheral venous plasma. The assay used [125I]diiodotyrosyl-alpha hANP, purified by high pressure liquid chromatography (HPLC), and a C-terminal-specific antiserum purchased from Peninsula Laboratories. Serial dilution curves of coronary sinus plasma samples were parallel with the standard curve, but significant nonparallelism was found in peripheral plasma samples of low immunoreactivity. When plasma was extracted using C-18 Sep-Pak cartridges, serial dilution curves from both coronary sinus and peripheral plasma samples were parallel to the standard curve. Although values for plasma samples assayed before and after extraction agreed closely (r = 0.99; n = 76), immunoreactive ANP in unextracted plasma was consistently greater (70-79 pmol/liter) than in extracts of plasma, suggesting non-specific interference by a component in plasma when assayed without extraction. Mean plasma immunoreactive ANP in 19 normal subjects consuming a normal salt intake was 14 +/- 1 (+/- SE) pmol/liter. In 5 normal men, increasing dietary sodium intake from 10 to 200 mmol sodium/day was associated with a 2-fold increment in ANP levels, and similar changes accompanied acute sodium loading using iv saline. Elevated values were found in patients with congestive heart failure (mean, 58 pmol/liter; range, 0-200; n = 9), chronic renal failure (mean, 118 pmol/liter; range, 30-290; n = 8), and primary aldosteronism (range, 32-90 pmol/liter; n = 3). HPLC and gel chromatographic analysis of the immunoreactive material found in coronary sinus plasma extracts showed that a large amount of the material eluted in the position of alpha hANP. A smaller quantity of immunoreactive material with a mol wt of about 1600 was also identified. Peripheral venous plasma extracts also contained several immunoreactive components, the largest amount of which corresponded to alpha hANP. The pattern of immunoreactive components in peripheral venous plasma, as identified by both gel chromotography and HPLC, was similar to that in coronary sinus plasma drawn during an active phase of hormone secretion. These findings indicate that the heart secretes alpha hANP or a closely similar peptide which is also present in peripheral venous plasma. Plasma immunoreactive ANP is responsive to sodium loading in normal man and is elevated in patients with hypervolemic disorders.
Collapse
|
16
|
Duff H, Renouf P, Macgregor DC, McLaughlin PR. Valve replacement for isolated mitral regurgitation. Can J Surg 1980; 23:141-5. [PMID: 7363174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
|